HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

American Heart Association

AHA 2022 Top Data Review

November 13, 2022

Our editorial team has compiled a list of the top data and news from the American Heart Association 2022 Scientific Sessions, with a focus on heart failure, hypertension, and lipid management.

SPORT: Supplements Fail to Lower LDL-C in Primary Prevention Population

November 08, 2022

Erin Michos, MD, provides further insight in an on-site interview AHA 22 related to results of the SPORT trial, which provide direct comparative insights into the impact of several dietary supplements and placebo therapy relative to low-dose statin therapy in a primary prevention cohort.

Phase 2 Data Shows Promise for Baxdrostat in Treatment-Resistant Hypertension

November 07, 2022

Phase 2 data from the BrigHTN trial suggest use of 2 mg baxdrostat was associated with significantly and substantially reduced systolic and diastolic blood pressure in patients with treatment-resistant hypertension. In a Q&A, trial investigator Deepak Bhatt, MD, MPH, provides further insight.

BEST-CLI: Surgery Best for Avoiding Amputation in PAD Patients

November 07, 2022

Data from a pair of presentations at AHA 2022 Scientific Sessions provide clinicians with insight into the effects of surgical vs endovascular procedures for improving prognosis and reducing amputation in patients with peripheral artery disease.

Don't Miss a Beat: AHA 2022

November 07, 2022

In this episode of Don't Miss a Beat, hosts Muthiah Vaduganathan, MD, MPH, and Stephen Greene, MD, are bringing you insights from the AHA 2022 Scientific Sessions. In the episode, which was recorded on day 2 of the 3-day meeting, our hosts offer listeners perspective on the EMPA-KIDNEY and the TRANSFORM-HF trial, the latter of which Greene served on as an investigator.

Ocean(a)-DOSE: Olpasiran Shows Promise for Lowering Lipoprotein(a)

November 06, 2022

Results of the Ocean(a)-DOSE trial, a phase 2 dose-finding study presented at AHA 22, suggests use of olpasiran dosed at 75 mg or higher every 12 weeks was associated with a reduction of Lp(a) among 95% of patients.